[{"id":"1889266c-a5ce-4ecd-95ad-5b5f5df04c63","acronym":"","url":"https://clinicaltrials.gov/study/NCT05668585","created_at":"2022-12-30T14:58:29.873Z","updated_at":"2024-07-02T16:35:06.423Z","phase":"Phase 1/2","brief_title":"A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors","source_id_and_acronym":"NCT05668585","lead_sponsor":"C4 Therapeutics, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation • BRAF V600","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Mekinist (trametinib) • CFT1946"],"overall_status":"Recruiting","enrollment":" Enrollment 206","initiation":"Initiation: 12/08/2022","start_date":" 12/08/2022","primary_txt":" Primary completion: 03/11/2027","primary_completion_date":" 03/11/2027","study_txt":" Completion: 04/11/2027","study_completion_date":" 04/11/2027","last_update_posted":"2024-05-02"}]